HYMPAVZI (Pfizer Australia Pty Ltd)
Product name
HYMPAVZI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
173 (255 working days)
Active ingredients
marstacimab
Registration type
NCE/ NBE
Indication
Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older with:
- severe haemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors, or
- severe haemophilia B (congenital factor IX deficiency, FIX <1%) without factor IX inhibitors.